Harvey Klingensmith's most recent trade in Core Laboratories N.V. was a trade of 9,317 Restricted Shares done . Disclosure was reported to the exchange on April 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Core Laboratories N.V. | Harvey Klingensmith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 9,317 | 0 | - | - | Restricted Shares | |
| Core Laboratories N.V. | Harvey Klingensmith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 9,317 | 41,962 (0%) | 0% | 0 | Common Stock | |
| Core Laboratories N.V. | Harvey Klingensmith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 8,069 | 8,069 | - | - | Restricted Shares | |
| Core Laboratories N.V. | Harvey Klingensmith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 9,317 | 9,317 | - | - | Restricted Shares | |
| Core Laboratories N.V. | Harvey Klingensmith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 6,419 | 32,645 (0%) | 0% | 0 | Common Stock | |
| Core Laboratories N.V. | Harvey Klingensmith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 6,419 | 0 | - | - | Restricted Shares | |
| Core Laboratories N.V. | Harvey Klingensmith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 6,419 | 6,419 | - | - | Restricted Shares | |
| Core Laboratories N.V. | Harvey Klingensmith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2023 | 5,485 | 0 | - | - | Restricted Shares | |
| Core Laboratories N.V. | Harvey Klingensmith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2023 | 5,485 | 26,226 (0%) | 0% | 0 | Common Shares | |
| Core Laboratories N.V. | Harvey Klingensmith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 5,485 | 5,485 | - | - | Restricted Shares | |
| Core Laboratories N.V. | Harvey Klingensmith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 4,307 | 20,741 (0%) | 0% | 0 | Common Shares | |
| Core Laboratories N.V. | Harvey Klingensmith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 4,307 | 0 | - | - | Restricted Shares | |
| Core Laboratories N.V. | Harvey Klingensmith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2021 | 14,507 | 0 | - | - | Restricted Shares | |
| Core Laboratories N.V. | Harvey Klingensmith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2021 | 14,507 | 16,507 (0%) | 0% | 0 | Common Shares | |
| Core Laboratories N.V. | Harvey Klingensmith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 4,307 | 4,307 | - | - | Restricted Shares | |
| Core Laboratories N.V. | Harvey Klingensmith | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.10 per share. | 01 Apr 2021 | 73 | 16,434 (0%) | 0% | 30.1 | 2,197 | Common Shares |